The Greater Baltimore Committee announced June 5 David S. Block, MD, president and CEO of Gliknik, Inc. has been named chair of the Greater Baltimore Committee’s Bioscience Committee. Dr. Block was chosen because of his leadership in the greater Baltimore bioscience community and his history of successful bioscience entrepreneurship. “A key priority for this committee going forward will be supporting the creation and growth of innovative bioscience companies by … Continue reading →

Last week, the GBC offered testimony supporting SB 405, a bill to add greater public-private sector balance to the Life Sciences Advisory Board by increasing its number of life science business members from four members to seven, and requiring at least four of those business members represent the small business community. Read the full testimony.

The Greater Baltimore Committee last week offered testimony supporting a bill intended to more aggressively focus use of the state’s stem cell research funding on supporting commercialization of research. HB 289, sponsored by Delegate Brian Feldman (D-Montgomery), requires that at least one-third of grants be awarded to for-profit companies in the state. It also requires that, in selecting nonprofit grant recipients, priority be given to applicants that have co-development partnerships … Continue reading →

CEOs and companies from Maryland’s biotech community were honored today by the Greater Baltimore Committee as winners of the sixth annual Maryland Bioscience Awards.  The awards were presented during a breakfast ceremony at the University of Maryland, Baltimore BioPark.   Winners of the 2011 Bioscience Awards are: Best New Product or Progress: Steven J. Kubisen, Ph.D., President and CEO, Seguro Surgical, Inc., Columbia.  The core technology for Seguro Surgical’s first … Continue reading →

By Donald C. Fry Well over 200 entrepreneurs and business advocates descended on Annapolis earlier this week to urge state lawmakers to enact an O’Malley administration proposal that would create Invest Maryland – a premium tax credit program aimed at generating $100 million in private investment funding from insurance companies for early-stage bioscience and technology businesses in Maryland. Speaking to individual lawmakers and testifying to two key budget committees, advocates … Continue reading →

More than 200 entrepreneurs and bioscience, technology and business advocates descended on Annapolis on February 16 to urge state lawmakers to enact an administration bill that would create Invest Maryland – a premium tax credit program aimed at generating $100 million in private investment funding for emerging Maryland businesses. Under the proposals, tax credits would be issued to participating insurance companies that contribute capital to the fund for investments in … Continue reading →

Small business owners, bioscience and technology industry entrepreneurs, and business advocates are expected to jam into hearing rooms in Annapolis on Wednesday as the General Assembly’s two key budget committees hear an administration bill to create Invest Maryland — premium tax credit program aimed at generating $100 million in private investment funding for emerging Maryland businesses. The bills, SB 180 and HB 173, will be heard at 1 p.m. before … Continue reading →